Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Toronto Public Health says it observed “many deviations from best practices” during an inspection at the gynecologist's ...
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Baystate Wing Hospital in Palmer, Mass., has contacted an unknown number of patients who may have been exposed to hepatitis or HIV due to a potential sterilization issue during surgeries performed ...
The letter said patients who received endometrial biopsies, IUD insertions or had cervical growths removed at the clinic ...
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...